BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pelcitoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pelcitoclax\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05691504-2350@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Pelcitoclax: Phase 1 readout est. (NCT05691504)
DESCRIPTION:Pelcitoclax\, phase 1.\nStudy: Testing the Combination of APG-1
 252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Can
 cers\nEstimated primary completion: 1 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pelcitoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05691504
URL:https://assetmemo.bio/drug/pelcitoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508982-2350@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20291212
DTEND;VALUE=DATE:20291213
SUMMARY:Pelcitoclax: Phase 1/2 readout est. (NCT07508982)
DESCRIPTION:Pelcitoclax\, phase 1/2.\nStudy: Phase1b/2 Trial Of AZA + APG12
 52 In Patients With High-Risk AML\nEstimated primary completion: 12 Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pelcitoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0750
 8982
URL:https://assetmemo.bio/drug/pelcitoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
